We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic
Read MoreHide Full Article
Key Takeaways
Illumina agreed to acquire SomaLogic for $350M plus up to $75M in milestone payments and royalties.
The deal enhances ILMN's multiomics roadmap and expands its presence in the proteomics market.
Illumina expects the SomaLogic business to turn profitable by 2027 with strong non-GAAP margin potential.
Illumina, Inc. (ILMN - Free Report) recently entered into a definitive agreement with Standard BioTools (LAB - Free Report) to acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets. The transaction is valued at $350 million in cash payable at closing, subject to customary adjustments, with additional payments of up to $75 million in near-term performance-based milestones and performance-based royalties.
The acquisition is set to enhance Illumina's presence in the expanding proteomics market and advance the highly ambitious multiomics strategy announced last year. The company plans to close the deal in the first half of 2026.
ILMN Stock’s Likely Trend Following the News
Since the June 23 announcement, ILMN shares jumped 2.9% to close at $93.23 yesterday. Illumina Protein Prep is already being used by nearly 40 early-access customers globally and will become broadly available starting in the third quarter of 2025. Combining SomaLogic's proteomics technology with its scalable NGS ecosystem, DRAGEN software and Illumina Connected Multiomics will speed up the technology development roadmap for proteomics and reduce the time and cost of proteomic research. Accordingly, the market sentiment surrounding ILMN stock is expected to remain positive, driven by this news.
Illumina presently has a market capitalization of $14.49 billion. The company’s earnings yield of 4.6% sits comfortably against the industry’s -27.7% yield. It delivered an earnings beat of 56.4%, on average, in the trailing four quarters.
Importance of ILMN’s New Acquisition
The latest transaction builds on a co-development agreement formed in December 2021, where Illumina and SomaLogic agreed to bring in the SomaScan Proteomics Assay on ILMN’s high-throughput next-generation sequencing (NGS) platforms. Over the past year, scientific evidence presented has highlighted the strength of SomaLogic's proteomics offerings in the areas of plexity, scalability and technical reproducibility. Researchers can also generate significant and impactful insights with high sensitivity, high throughput and thousands of protein markers in a single experiment.
Image Source: Zacks Investment Research
SomaLogic has approximately 250 employees worldwide working in commercial, research and development (R&D), lab operations, manufacturing and other roles. The company's Boulder, CO, facilities — including a CLIA- and CAP-certified lab, office and manufacturing space — will be included in the purchase.
Further, Illumina will add SomaLogic's aptamer-based affinity proteomics platform to its portfolio. The kitted NGS-based panel business will add a high-margin consumable revenue stream. Assuming the deal closes as planned, Illumina expects this business to become profitable in 2027 on a non-GAAP operating income basis and for non-GAAP operating margins to align with Illumina in 2028.
Industry Prospects Favor ILMN
According to a Research report, the global proteomics market is estimated to be worth $41.65 billion in 2025 and expand at a compound annual growth rate (CAGR) of 14.9% by 2034. The growth of the market is likely to be fueled by ongoing R&D in the field and the use of high-quality tools for research purposes. Further, the growing need for personalized medicines, and constant collaborations and partnerships are also likely to drive the market expansion.
More Updates From Illumina
In May, the company unveiled a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. Built on state-of-the-art deep learning neural networks, PromoterAI turns data into insights, helping researchers accelerate new breakthroughs in the diagnosis of rare diseases.
ILMN Stock Price Performance
In the past month, ILMN shares have risen 14% compared with the industry’s 2.5% growth.
Illumina’s Zacks Rank and Key Picks
Illumina currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) and Hims & Hers Health (HIMS - Free Report) . While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have jumped 5.2% to $2.04 in the past 30 days. Shares of the company have rallied 43.8% in the past year compared with the industry’s 12.1% growth. Its earnings yield of 8.2% compares comfortably with the industry’s 0.9% yield. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%.
Hims & Hers Health shares have surged 108.8% in the past year. Estimates for the company’s 2025 earnings per share have jumped 17.7% to 73 cents in the past 30 days. HIMS’ earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic
Key Takeaways
Illumina, Inc. (ILMN - Free Report) recently entered into a definitive agreement with Standard BioTools (LAB - Free Report) to acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets. The transaction is valued at $350 million in cash payable at closing, subject to customary adjustments, with additional payments of up to $75 million in near-term performance-based milestones and performance-based royalties.
The acquisition is set to enhance Illumina's presence in the expanding proteomics market and advance the highly ambitious multiomics strategy announced last year. The company plans to close the deal in the first half of 2026.
ILMN Stock’s Likely Trend Following the News
Since the June 23 announcement, ILMN shares jumped 2.9% to close at $93.23 yesterday. Illumina Protein Prep is already being used by nearly 40 early-access customers globally and will become broadly available starting in the third quarter of 2025. Combining SomaLogic's proteomics technology with its scalable NGS ecosystem, DRAGEN software and Illumina Connected Multiomics will speed up the technology development roadmap for proteomics and reduce the time and cost of proteomic research. Accordingly, the market sentiment surrounding ILMN stock is expected to remain positive, driven by this news.
Illumina presently has a market capitalization of $14.49 billion. The company’s earnings yield of 4.6% sits comfortably against the industry’s -27.7% yield. It delivered an earnings beat of 56.4%, on average, in the trailing four quarters.
Importance of ILMN’s New Acquisition
The latest transaction builds on a co-development agreement formed in December 2021, where Illumina and SomaLogic agreed to bring in the SomaScan Proteomics Assay on ILMN’s high-throughput next-generation sequencing (NGS) platforms. Over the past year, scientific evidence presented has highlighted the strength of SomaLogic's proteomics offerings in the areas of plexity, scalability and technical reproducibility. Researchers can also generate significant and impactful insights with high sensitivity, high throughput and thousands of protein markers in a single experiment.
Image Source: Zacks Investment Research
SomaLogic has approximately 250 employees worldwide working in commercial, research and development (R&D), lab operations, manufacturing and other roles. The company's Boulder, CO, facilities — including a CLIA- and CAP-certified lab, office and manufacturing space — will be included in the purchase.
Further, Illumina will add SomaLogic's aptamer-based affinity proteomics platform to its portfolio. The kitted NGS-based panel business will add a high-margin consumable revenue stream. Assuming the deal closes as planned, Illumina expects this business to become profitable in 2027 on a non-GAAP operating income basis and for non-GAAP operating margins to align with Illumina in 2028.
Industry Prospects Favor ILMN
According to a Research report, the global proteomics market is estimated to be worth $41.65 billion in 2025 and expand at a compound annual growth rate (CAGR) of 14.9% by 2034. The growth of the market is likely to be fueled by ongoing R&D in the field and the use of high-quality tools for research purposes. Further, the growing need for personalized medicines, and constant collaborations and partnerships are also likely to drive the market expansion.
More Updates From Illumina
In May, the company unveiled a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. Built on state-of-the-art deep learning neural networks, PromoterAI turns data into insights, helping researchers accelerate new breakthroughs in the diagnosis of rare diseases.
ILMN Stock Price Performance
In the past month, ILMN shares have risen 14% compared with the industry’s 2.5% growth.
Illumina’s Zacks Rank and Key Picks
Illumina currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) and Hims & Hers Health (HIMS - Free Report) . While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have jumped 5.2% to $2.04 in the past 30 days. Shares of the company have rallied 43.8% in the past year compared with the industry’s 12.1% growth. Its earnings yield of 8.2% compares comfortably with the industry’s 0.9% yield. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%.
Hims & Hers Health shares have surged 108.8% in the past year. Estimates for the company’s 2025 earnings per share have jumped 17.7% to 73 cents in the past 30 days. HIMS’ earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%.